Therapy Areas: Vaccines
GRAM to manufacture Johnson & Johnson's SARS-CoV-2 vaccine candidate
28 September 2020 -

Contract development injectable company Grand River Aseptic Manufacturing (GRAM) announced on Friday that it has signed an agreement to support the manufacture of Johnson & Johnson's Janssen Pharmaceuticals Inc SARS-CoV-2 vaccine candidate.

This agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson's SARS-CoV-2 vaccine candidate to GRAM's new, state-of-the-art facility and now swiftly preparing for the start of vaccine production.

The Johnson & Johnson vaccine candidate being manufactured at GRAM is being developed, in part, with funding from BARDA. BARDA, in collaboration with JPEO-CBRND, is funding a demonstration of manufacturing capability that is expected to result in 100m doses of the investigational vaccine which the federal government will own.

Through advanced aseptic fill and finish services, GRAM's Johnson & Johnson's COVID-19 vaccine candidate would be available upon regulatory approval. GRAM will utilize its world-class 60,000 sq. ft. large-scale fill and finish facility located in Grand Rapids, MI.

Login
Username:

Password: